FIGURE LEGENDS
Figure 1. Associations of hair arsenic concentration with intensity of itch. (A) Continuous NRS for itch; (B) moderate itch, NRS≥3; (C) severe itch, NRS≥7.
Figure 2. Continuous and categorical models of PRSMMA% and PRSDMA% with the prevalence of pruritus in participants of the UK Biobank. DMA, dimethylated arsenic; MMA, monomethylated arsenic; PRS, polygenic risk score.
Figure 3. Serum concentrations of itch biomarkers in controls and patients with mild and severe itch. (A) β-endorphin; (B) substance P; (C) nerve growth factor; (D) histamine; (E) interleukin-31; (F) IgE; (G) endothelin-1; (H) 5-hydroxytryptamine.
Figure 4. The concentrations of β-endorphin in the arsenite-treated mice.
Figure 5. Intensity of itch in naloxone versus placebo groups in the baseline and follow-up periods. The bars signify 95% confidence intervals of the means.